Abstract
Solid-organ transplant recipients are at higher risk of developing Kaposi sarcoma, which is a multicentric vascular neoplasm of lymphatic endothelium-derived cells. Reducing doses of immunosuppressive drugs and switching from calcineurin inhibitors to the mammalian target of rapamycin inhibitor rapamycin have been suggested as an effective first-line treatment modality in most patients. Herein, we report a 64-year-old renal transplant recipient who developed multiple cutaneous and visceral Kaposi sarcoma lesions 2 months after transplant. The patient showed no improvement, with progression of the disease until month 15 of the suggested therapy of rapamycin.
MeSH terms
-
Antibiotics, Antineoplastic / administration & dosage*
-
Antibiotics, Antineoplastic / adverse effects
-
Drug Substitution
-
Female
-
Humans
-
Immunocompromised Host
-
Immunosuppressive Agents / administration & dosage*
-
Immunosuppressive Agents / adverse effects
-
Kidney Transplantation / adverse effects*
-
Middle Aged
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / adverse effects
-
Sarcoma, Kaposi / chemically induced
-
Sarcoma, Kaposi / drug therapy*
-
Sarcoma, Kaposi / immunology
-
Sarcoma, Kaposi / pathology
-
Sirolimus / administration & dosage*
-
Sirolimus / adverse effects
-
Skin Neoplasms / chemically induced
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / immunology
-
Skin Neoplasms / pathology
-
TOR Serine-Threonine Kinases / antagonists & inhibitors
-
Treatment Outcome
Substances
-
Antibiotics, Antineoplastic
-
Immunosuppressive Agents
-
Protein Kinase Inhibitors
-
MTOR protein, human
-
TOR Serine-Threonine Kinases
-
Sirolimus